AIGH Capital Management LLC Has $13.93 Million Holdings in Personalis, Inc. (NASDAQ:PSNL)

AIGH Capital Management LLC boosted its holdings in shares of Personalis, Inc. (NASDAQ:PSNL - Free Report) by 4.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,968,948 shares of the company's stock after purchasing an additional 169,884 shares during the period. Personalis makes up approximately 5.8% of AIGH Capital Management LLC's holdings, making the stock its 3rd biggest position. AIGH Capital Management LLC owned about 4.49% of Personalis worth $13,931,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in PSNL. Raymond James Financial Inc. acquired a new position in shares of Personalis during the 4th quarter worth $64,000. American Century Companies Inc. lifted its holdings in shares of Personalis by 98.8% during the 4th quarter. American Century Companies Inc. now owns 50,321 shares of the company's stock worth $291,000 after acquiring an additional 25,011 shares during the period. EntryPoint Capital LLC bought a new position in Personalis during the 4th quarter valued at about $275,000. JPMorgan Chase & Co. lifted its holdings in Personalis by 2,827.0% during the 4th quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company's stock valued at $34,000 after purchasing an additional 5,654 shares during the last quarter. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its holdings in Personalis by 66.6% during the 4th quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 25,168 shares of the company's stock valued at $145,000 after purchasing an additional 10,065 shares during the last quarter. Hedge funds and other institutional investors own 61.91% of the company's stock.

Personalis Price Performance

NASDAQ PSNL traded down $0.26 on Friday, hitting $6.46. 270,151 shares of the stock were exchanged, compared to its average volume of 1,056,372. The business's fifty day moving average is $5.95 and its 200 day moving average is $4.91. Personalis, Inc. has a 52 week low of $2.81 and a 52 week high of $7.79. The company has a market capitalization of $570.14 million, a PE ratio of -5.00 and a beta of 1.95.

Personalis (NASDAQ:PSNL - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.05. Personalis had a negative net margin of 98.10% and a negative return on equity of 48.78%. The firm had revenue of $20.61 million for the quarter, compared to the consensus estimate of $17.41 million. Analysts predict that Personalis, Inc. will post -1.4 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on PSNL shares. Guggenheim started coverage on shares of Personalis in a research report on Thursday, May 15th. They set a "buy" rating and a $6.00 price target for the company. HC Wainwright boosted their price objective on shares of Personalis from $8.00 to $9.00 and gave the company a "buy" rating in a report on Wednesday, May 7th. Finally, Needham & Company LLC restated a "buy" rating and set a $7.00 price objective on shares of Personalis in a report on Thursday, April 10th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $7.67.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.